Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1999

View Archived Issues

Rhone-Poulenc Rorer identifies new farnesyltransferase inhibitor series

FDA accepts PMA for OP-1 Implant

Ilex Oncology: Q2 1999 highlights

Millennium reaches milestone in cancer collaboration with Lilly

LeukoSite: Q2 1999 highlights

SuperGen completes Sparta acquisition

Medi-Ject proceeds with development of needle-free device for male impotence therapy

Ribozyme presents positive data on Angiozyme cancer therapy

InSite Vision licenses AquaSite to SSP in Japan

New transplant agent marketed by Roche in U.K.

Pentose files IND with FDA for Inactine viral inactivation technology

FDA approves new insomnia treatment

Study hints that PAF antagonist may be effective in AIDS dementia

Cytran and Alza enter agreement for IM-862

Etanercept trial results in psoriatic arthritis announced

Oxazolidinone antibacterial agent available for licensing from BTG

Pasteur Merieux Connaught and Zycos collaborate on cancer vaccine research

Immune Network Research forms JV with Bridge Pharma to develop asthma drug

Results of canine study support conivaptan efficacy in CHF

Company Profile: Atairgin Technologies

Selective ETB receptor antagonist identified by Abbott

Sanofi-Synthelabo, Akzo Nobel collaborate in the study of factor Xa inhibitors

CPMP declines to recommend approval of saruplase marketing application

Novel platelet ADP inhibitors reported by Cor Therapeutics

Korean researchers synthesize orally active penciclovir prodrug

Scriptgen presents triazine compounds for treating DNA and RNA viral diseases

Cell adhesion inhibitor series has potential application in inflammatory and immune disorders

Kissei prepares beta3-adrenoceptor stimulants as novel antiobesity agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...